Neuroinfections and antimicrobials: do we need new molecules or new strategies?

Kalavsky E, Kisac P, Huttova M, Benca J, Krcmery V.
  Vol. 28 (Suppl 2) 2007 Neuro endocrinology letters Journal Article   2007; 28(Suppl 2): 38-39 PubMed PMID:  17558378    Citation  Keywords:  Anti-Infective Agents:therapeutic use, Brain Diseases:drug therapy, Candidiasis:drug therapy, Cross Infection:drug therapy, Drug Resistance, Microbial, Fluconazole:therapeutic use, Humans, Meningitis:drug therapy, Pseudomonas Infections:drug therapy, Stap.   

: Within last 15 years, analyzing patterns of etiology and resistance in organisms causing neuroinfections, emergence of resistance has been observed in Slovakia in S. haemolyticus to teicoplanin (11%), Ps. aeruginosa and A. baumannii to meropenem (20%) and Candida spp. (non-albicans Candida spp.) to fluconazol (20%). There are no new antibiotics against carbapenem resistant Ps. aeruginosa and Acinetobacter baumannii.